Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.

21/01/2025

GMT Eight

Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company received the "Drug Registration Certificate" for the sodium bromfenac eye drops issued by the National Medical Products Administration. The sodium bromfenac eye drops approved this time are used for symptomatic treatment of inflammatory diseases of the external and anterior parts of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.

Jiang Cheng's fund quarterly report released! The top ten major holdings remain largely unchanged, and he sees long-term potential in the Chinese economy.

Guangdong Mingyang Electric (301291.SZ) is forecasting a net profit of 600 million to 700 million yuan for the year, a year-on-year increase of 21.18% to 41.37%.

Contact: contact@gmteight.com

Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.

RECOMMEND

Tianjin Guoan Mengguli New Materials Science & Technology (301487.SZ) expects to make a pre-tax loss, predicting a net loss of 65-80 million yuan for the year 2024, leading from profit to loss.

Hwa Create Corporation (300045.SZ) forecasts a net loss of 98 to 136 million yuan in 2024.

Jiangsu Sihuan Bioengineering (000518.SZ): Qiu Weibi will become the actual controlling shareholder of the company.